Compare GLP & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | SANA |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 4700 | N/A |
| Industry | Oil Refining/Marketing | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | GLP | SANA |
|---|---|---|
| Price | $46.54 | $3.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $46.00 | $7.80 |
| AVG Volume (30 Days) | 37.6K | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.44% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $64.13 | N/A |
| Revenue Next Year | $11.74 | N/A |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.58 | $1.63 |
| 52 Week High | $56.51 | $6.55 |
| Indicator | GLP | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 46.89 |
| Support Level | $45.78 | $2.84 |
| Resistance Level | $48.48 | $3.43 |
| Average True Range (ATR) | 1.54 | 0.28 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 50.59 | 25.70 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.